Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study

Radiotherapy and Oncology

Volumn 95, Issue 3, 2010, Pages 292-297

  Gunnlaugsson, Adalsteinn ^a   Anderson, Harald ^b   Lind, Pehr ^c   Glimelius, Bengt ^c,d   Johnsson, Anders ^a  

^a

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biliary tract cancer; Capecitabine; Oxaliplatin; Pancreatic cancer; Radiotherapy

Indexed keywords

CAPECITABINE; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BILIARY TRACT CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION SICKNESS; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CA-19-9 ANTIGEN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 77952582556     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.04.004     Document Type: Article

References (29)

1. Sultana A., Tudur Smith C., Cunningham D., et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96 (2007) 1183-1190
2. Baisden J.M., Kahaleh M., Weiss G.R., et al. Multimodality treatment with helical tomotherapy intensity modulated radiotherapy, capecitabine, and photodynamic therapy is feasible and well tolerated in patients with hilar cholangiocarcinoma. Gastrointest Cancer Res 2 (2008) 219-224
3. Ben-David M.A., Griffith K.A., Abu-Isa E., et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 66 (2006) 772-779
4. Kjellstrom J., Kjellen E., and Johnsson A. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol 44 (2005) 687-693
5. Gunnlaugsson A., Anderson H., Fernebro E., et al. Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study. Eur J Cancer 45 (2009) 807-813
6. Rodel C., Liersch T., Hermann R.M., et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25 (2007) 110-117
7. Machiels J.P., Duck L., Honhon B., et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 16 (2005) 1898-1905
8. Xiong H.Q., Varadhachary G.R., Blais J.C., et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113 (2008) 2046-2052
9. Nehls O., Oettle H., Hartmann J.T., et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 98 (2008) 309-315
10. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47 (2000) 13-47
11. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 92 (2000) 205-216
12. Kalbfleisch J.D., and Prentice R.L. The statistical analysis of failure time data (1980), John Wiley and Sons, New York
13. Saif M., Black G., Shalija R., et al. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J 13 (2007) 247-256
14. Goldstein D., Van Hazel G., Walpole E., et al. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer 97 (2007) 464-471
15. Morganti A.G., Valentini V., Macchia G., et al. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: phase I-II dose-escalation study. Int J Radiat Oncol Biol Phys 59 (2004) 1454-1460
16. Cohen S.J., Dobelbower R.J., Lipsitz S., et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62 (2005) 1345-1350
17. Lind P.A., Isaksson B., Almstrom M., et al. Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma. Acta Oncol. 47 (2008) 413-420
18. Chauffert B., Mornex F., Bonnetain F., et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19 (2008) 1592-1599
19. Small Jr. W., Berlin J., Freedman G.M., et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol 26 (2008) 942-947
20. Chengiz M., Zorlu F., Yalcin S., et al. Concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Med Oncol 24 (2007) 239-243
21. Kurt E., Kurt M., Kanat O., et al. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer. Tumori 92 (2006) 481-486
22. Shinchi H., Takao S., Noma H., et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53 (2002) 146-150
23. Boeck S., Hoehler T., Seipelt G., et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 19 (2008) 340-347
24. Nehls O., Oettle H., Hartmann J.T., et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 98 (2008) 309-315
25. Krishnan S., Rana V., Janjan N.A., et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 110 (2007) 47-55
26. Reni M., Cereda S., Balzano G., et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 115 (2009) 2630-2639
27. Hess V., Glimelius B., Grawe P., et al. CA19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. The Lancet Oncol 9 (2008) 132-138
28. Wong D., Ko A.H., Hwang J., et al. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas 37 (2008) 269-274
29. Locker G.Y., Hamilton S., Harris J., et al. ASCO 2006 of recommendations for the use of tumour markers in gastrointestinal cancer. J Clin Oncol 24 (2006) 5313-5327